{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}]}],"title":"Grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated analysis set included all participants who received JNJ-68284528 infusion.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 45.2 months","title":"Phase 1b: Number of Participants With Adverse Events as Per Severity","type":"PRIMARY","unitOfMeasure":"Participants"}